DEA schedule
Is alirocumab a controlled substance?
Federal schedule for alirocumab from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
No. Alirocumab is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and alirocumab is not on the DEA controlled substances list.
Run it in Rivvi
Which 2027 plans near you dropped or restricted alirocumab?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 4 prescription listings from 2 labelers, none with a DEA schedule |
| DEA controlled substances list | alirocumab is not on the list |
Alirocumab NDC listings
| NDC | Product | Form | Strength | Labeler | DEA schedule |
|---|---|---|---|---|---|
| 0024-5902 | Praluent | injection, solution | 150 mg/mL | Sanofi-Aventis U.S. LLC | None |
| 61755-021 | Praluent | injection, solution | 150 mg/mL | Regeneron Pharmaceuticals, Inc. | None |
| 0024-5901 | Praluent | injection, solution | 75 mg/mL | Sanofi-Aventis U.S. LLC | None |
| 61755-020 | Praluent | injection, solution | 75 mg/mL | Regeneron Pharmaceuticals, Inc. | None |
Questions
Is alirocumab a controlled substance?
No. Alirocumab is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and alirocumab is not on the DEA controlled substances list.
Is alirocumab a narcotic?
No. Alirocumab is not on the DEA controlled substances list, so the DEA does not classify it as a narcotic. Its FDA established pharmacologic class is PCSK9 Inhibitor.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.